» Articles » PMID: 11551238

IL-18 in Patients with Multiple Sclerosis

Overview
Specialty Neurology
Date 2001 Sep 12
PMID 11551238
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

IL-18 is a cytokine which plays an important role in Th-1 response through its ability to induce IFN-gamma production in T cells and NK cells. The purpose of the study was to measure IL-18 levels in serum and CSF of 21 patients with the relapsing-remitting form of MS, 9 with active gadolinium enhancing lesions in MRI and 12 without enhancing lesions, and to compare results with control group consisting of 11 patients with diagnosis of neurasthenia and tension headache. IL-18 concentration in the CSF and sera was measured by ELISA. We found a highly significant increase of both IL-18 CSF and serum levels in MS patients in comparison with the control group. In patients with active MRI lesions the levels of IL-18 in CSF and serum were significantly higher in comparison with the levels found in patients without enhancing lesions. The results suggest involvement of IL-18 in immunopathogenesis of MS especially in the active stages of the disease.

Citing Articles

IL-18 Blockage Reduces Neuroinflammation and Promotes Functional Recovery in a Mouse Model of Spinal Cord Injury.

Begum E, Mahmod M, Rahman M, Fukuma F, Urano T, Fujita Y Biomolecules. 2025; 15(1.

PMID: 39858411 PMC: 11761924. DOI: 10.3390/biom15010016.


Selected Interleukins Relevant to Multiple Sclerosis: New Directions, Potential Targets and Therapeutic Perspectives.

Mado H, Stasiniewicz A, Adamczyk-Sowa M, Sowa P Int J Mol Sci. 2024; 25(20).

PMID: 39456713 PMC: 11506881. DOI: 10.3390/ijms252010931.


Multiple sclerosis: the NLRP3 inflammasome, gasdermin D, and therapeutics.

Brint A, Greene S, Fennig-Victor A, Wang S Ann Transl Med. 2024; 12(4):62.

PMID: 39118955 PMC: 11304424. DOI: 10.21037/atm-23-1960.


Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation.

van den Bosch A, van der Poel M, Fransen N, Vincenten M, Bobeldijk A, Jongejan A Nat Commun. 2024; 15(1):1667.

PMID: 38396116 PMC: 10891081. DOI: 10.1038/s41467-024-46068-3.


Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review).

Fathallah S, Abdellatif A, Saadeldin M Med Int (Lond). 2023; 3(5):42.

PMID: 37680650 PMC: 10481116. DOI: 10.3892/mi.2023.102.